US 11,891,449 B2
Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereof
Wenzhi Tian, Shanghai (CN); Song Li, Shanghai (CN); and Dianze Chen, Shanghai (CN)
Assigned to IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC., Shanghai (CN)
Filed by Immuneonco Biopharmaceuticals (Shanghai) Inc., Shanghai (CN)
Filed on Dec. 6, 2021, as Appl. No. 17/543,033.
Claims priority of application No. 202111195248.4 (CN), filed on Oct. 13, 2021.
Prior Publication US 2023/0114491 A1, Apr. 13, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/02 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/02 (2018.01); C07K 2317/24 (2013.01); C07K 2317/66 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
 
1. A recombinant fusion protein, comprising an anti-CD24 antibody or an antibody fragment thereof, and a CD47 binding peptide,
wherein the anti-CD24 antibody or antibody fragment thereof comprises a heavy chain variable region, a heavy chain constant region, and a light chain variable region, wherein the heavy chain variable region comprises a heavy chain variable CDR-1 (HV-CDR1), a HV-CDR2 and a HV-CDR3 having amino acid sequences set forth in SEQ ID NOs: 7, 8 and 9, respectively, the light chain variable region comprises a light chain variable CDR-1 (LV-CDR1), a LV-CDR2 and a LV-CDR3 having amino acid sequences set forth in SEQ ID NOs: 10, 11 and 12, respectively, and the heavy chain constant region has Fc binding affinity and is linked to C-terminus of the heavy chain variable region,
wherein the CD47 binding peptide comprises a signal-regulatory protein (SIRP) extracellular domain having an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1,
wherein the CD47 binding peptide is linked to the anti-CD24 antibody or antibody fragment thereof.